José Manuel Mejía Oneto
Research Subjects
José Manuel Mejía Oneto has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Maša Alečković
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
20 shared publications - Sangeetha Srinivasan
Shasqi Inc., San Francisco, California
20 shared publications - Tri-Hung Nguyen
Shasqi Inc., San Francisco, California
20 shared publications - Alexander D. Guminski
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
19 shared publications - Amir Mahmoodi
Shasqi Inc., San Francisco, California
19 shared publications - Michael Zakharian
Shasqi Inc., San Francisco, California
19 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S6. SQ3370 induces changes in the immune microenvironment of MC38 tumors.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S6. SQ3370 induces changes in the immune microenvironment of MC38 tumors.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S8. SQ3370-001 patient dose escalation.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S8. SQ3370-001 patient dose escalation.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S2 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Data S2: Structure of Trans-Cyclooctene-Dox-Alanine
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S2 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Data S2: Structure of Trans-Cyclooctene-Dox-Alanine
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S10. Click chemistry surpasses translatability of previous Dox-based approaches.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S10. Click chemistry surpasses translatability of previous Dox-based approaches.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S9. Immune analysis of patient samples after SQ3370 treatment.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S9. Immune analysis of patient samples after SQ3370 treatment.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S7. Pharmacokinetics of Dox activation with SQ3370 in dogs
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S7. Pharmacokinetics of Dox activation with SQ3370 in dogs
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Data S1. Antibody panels for immune profiling of mouse tumors by flow cytometric analysis.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Data S1. Antibody panels for immune profiling of mouse tumors by flow cytometric analysis.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S5. Reduced B16-F10 tumor volume after single and multiple SQ3370 cycles is associated with small, but reversible body weight loss.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S5. Reduced B16-F10 tumor volume after single and multiple SQ3370 cycles is associated with small, but reversible body weight loss.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S4. Tumor Dox activation and distribution after control treatments in a mouse tumor model.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Supplementary Fig S4. Tumor Dox activation and distribution after control treatments in a mouse tumor model.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Purpose:Achieving precise drug activation without associated toxicities is a significant challenge in developing cancer therapeutics. Click Activated Protodrugs Against Cancer is a pretargeting approach that uses bioorthogonal click chemistry in vivo to selectively capture and activate drugs at tumors and can be applied to a wide variety of targeted therapeutics. The first-in-class Click Activated Protodrugs Against Cancer–based cancer therapeutic SQ3370 uses a clickable pretargeting agent that reacts with a chemically attenuated clickable payload of doxorubicin (Dox) and releases the active cytotoxic drug in situ.Patients and Methods:We describe the preclinical development and translation of SQ3370 to a first-in-human dose-escalation clinical trial in adult patients with advanced solid tumors (NCT04106492).Results:SQ3370 inhibited tumor progression across several mouse tumor models through the safe and selective release of Dox in tumors at concentrations unachievable by conventional treatment. SQ3370 exhibited safety when administered at 8.9 times the veterinary Dox dose in dogs and 15 times the conventional Dox dose in patients, with no reported protocol-defined dose-limiting toxicities. In patients, SQ3370 modulated active Dox pharmacokinetics and enabled T-cell–dependent immune responses, including cytotoxic CD8+ T-cell expansion and activation in tumors and systemically.Conclusions:SQ3370, the first demonstration of click chemistry within the human body in a clinical setting, facilitated the delivery of chemotherapy to tumors and unlocked additional biological effects such as favorable immune responses that may benefit patients with metastasis. Consistent safety, toxicology, pharmacokinetic, and immune activation results observed across species highlight the translatability of the technology and position click chemistry as a powerful new modality for the development of targeted cancer therapeutics.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
Purpose:Achieving precise drug activation without associated toxicities is a significant challenge in developing cancer therapeutics. Click Activated Protodrugs Against Cancer is a pretargeting approach that uses bioorthogonal click chemistry in vivo to selectively capture and activate drugs at tumors and can be applied to a wide variety of targeted therapeutics. The first-in-class Click Activated Protodrugs Against Cancer–based cancer therapeutic SQ3370 uses a clickable pretargeting agent that reacts with a chemically attenuated clickable payload of doxorubicin (Dox) and releases the active cytotoxic drug in situ.Patients and Methods:We describe the preclinical development and translation of SQ3370 to a first-in-human dose-escalation clinical trial in adult patients with advanced solid tumors (NCT04106492).Results:SQ3370 inhibited tumor progression across several mouse tumor models through the safe and selective release of Dox in tumors at concentrations unachievable by conventional treatment. SQ3370 exhibited safety when administered at 8.9 times the veterinary Dox dose in dogs and 15 times the conventional Dox dose in patients, with no reported protocol-defined dose-limiting toxicities. In patients, SQ3370 modulated active Dox pharmacokinetics and enabled T-cell–dependent immune responses, including cytotoxic CD8+ T-cell expansion and activation in tumors and systemically.Conclusions:SQ3370, the first demonstration of click chemistry within the human body in a clinical setting, facilitated the delivery of chemotherapy to tumors and unlocked additional biological effects such as favorable immune responses that may benefit patients with metastasis. Consistent safety, toxicology, pharmacokinetic, and immune activation results observed across species highlight the translatability of the technology and position click chemistry as a powerful new modality for the development of targeted cancer therapeutics.